Novocure Limited (NVCR) Market Update
- Closing Price (21 Oct 2026): USD 15.81
- Trading Volume (last 24 h): USD 27.3 million
- Shares Outstanding: 116.2 million
- Market Capitalisation: USD 1.70 billion
- Price Change (last 24 h): +5.51 %
- Price Change (last month‑end): –4.96 %
- 200‑Day Simple Moving Average: USD 14.81
- 52‑Week High: USD 21.45 (24 Jul 2026)
- 52‑Week Low: USD 9.82 (09 Feb 2026)
Recent Analyst Commentary
Analysts note that Novocure’s shares appear undervalued relative to the company’s growth prospects. The stock’s recent rise reflects positive market sentiment regarding its strategic positioning and financial outlook.
Related Stock Movements (Last 24 h)
| Symbol | Price (Local Currency) | Change | Market Capitalisation |
|---|---|---|---|
| CTL.L | GBX 7.00 | –3.57 % | GBX 33.8 million |
| TORO.L | EUR 0.53 | +0.95 % | EUR 187.4 million |
| SRJ.AX | AUD 0.01 | –11.11 % | AUD 7.8 million |
| RYR.V | CAD 0.18 | –5.26 % | CAD 63.9 million |
| EJFZ.L | GBX 117.00 | 0.00 % | GBX 105.9 million |
Royal Road Minerals – Recent Activity
Royal Road Minerals (RYR.V) reported that surface sampling at the El Alemán site within its GAM project in Colombia has identified a gold‑bearing vein system extending at least 300 metres. The company plans drilling to test continuity, grade, and true thickness between surface and deeper intersections. Management highlights potential synergy with existing porphyry and skarn‑style mineralisation at Gúintr.
Company Overview
Novocure Limited is a healthcare company specialising in oncology solutions. The company develops and commercialises novel technologies for cancer treatment. Novocure operates globally as a provider of medical equipment and supplies. It is listed on the Nasdaq stock exchange, having completed its initial public offering on 2 October 2015. Further information is available on the company’s website at www.novocure.com .
